Updated on 15 October 2013
"We have been working on the CZ48 drug with the Stehlin Foundation for more than five years. We are glad that our HGCP technology is able to improve bioavailability, reduce drug dosage and side effects, as well as enhance the patient compliance of this highly potential drug. We will continue working closely with the Stehlin Foundation team to support their human clinical trials, commercialization and future developments," says Mr. David Sher, Managing Director, NMT.
Based on IMS Health Reports, anti-cancer drugs will remain the highest grossing sector of the healthcare industry with global sales estimated to reach USD83 billion by 2016. The CZ48 drug, together with Camptothecin and its other derivatives, has a potential market of USD1 billion in USA alone.